Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ).
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced the resolutions passed at its ninth board of directors’ twenty-ninth meeting. Key decisions include the approval of Guangzhou Guangyao’s acquisition of an 11.04% stake in Nanjing Pharmaceutical Company and the election of Chen Jiehui as the vice chairman of the board. These moves are expected to strengthen the company’s strategic position and enhance its governance structure.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company operates in the pharmaceutical industry, focusing on the development, production, and distribution of medicinal products.
YTD Price Performance: 3.65%
Average Trading Volume: 1,769,764
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.86B
For an in-depth examination of 0874 stock, go to TipRanks’ Overview page.